Switch theme
Sign up to access all valuation multiples
Iconovo AB develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The project is a generic version of the asthma and COPD product Symbicort.
2013
25
LTM Revenue $1.9M
LTM EBITDA -$1.7M
$1.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Iconovo has a last 12-month revenue (LTM) of $1.9M and a last 12-month EBITDA of -$1.7M.
In the most recent fiscal year, Iconovo achieved revenue of $0.3M and an EBITDA of -$3.1M.
Iconovo expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Iconovo valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.9M | XXX | $0.3M | XXX | XXX | XXX |
| Gross Profit | $1.9M | XXX | $2.0M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 652% | XXX | XXX | XXX |
| EBITDA | -$1.7M | XXX | -$3.1M | XXX | XXX | XXX |
| EBITDA Margin | -92% | XXX | -1015% | XXX | XXX | XXX |
| EBIT | -$2.9M | XXX | -$4.2M | XXX | XXX | XXX |
| EBIT Margin | -154% | XXX | -1400% | XXX | XXX | XXX |
| Net Profit | -$2.9M | XXX | -$4.2M | XXX | XXX | XXX |
| Net Margin | -154% | XXX | -1402% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Iconovo's stock price is SEK 1 (or $0).
Iconovo has current market cap of SEK 27.7M (or $2.9M), and EV of SEK 10.9M (or $1.1M).
See Iconovo trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1M | $2.9M | XXX | XXX | XXX | XXX | $-0.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Iconovo has market cap of $2.9M and EV of $1.1M.
Iconovo's trades at 3.7x EV/Revenue multiple, and -0.4x EV/EBITDA.
Equity research analysts estimate Iconovo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Iconovo has a P/E ratio of -1.0x.
See valuation multiples for Iconovo and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.9M | XXX | $2.9M | XXX | XXX | XXX |
| EV (current) | $1.1M | XXX | $1.1M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 3.7x | XXX | XXX | XXX |
| EV/EBITDA | -0.7x | XXX | -0.4x | XXX | XXX | XXX |
| EV/EBIT | -0.4x | XXX | -0.3x | XXX | XXX | XXX |
| EV/Gross Profit | 0.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.0x | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIconovo's last 12 month revenue growth is 212%
Iconovo's revenue per employee in the last FY averaged $12K, while opex per employee averaged $0.2M for the same period.
Iconovo's rule of 40 is -176% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Iconovo's rule of X is 438% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Iconovo and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 212% | XXX | 423% | XXX | XXX | XXX |
| EBITDA Margin | -92% | XXX | -1015% | XXX | XXX | XXX |
| EBITDA Growth | -137% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -176% | XXX | -803% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 438% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $12K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2052% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Iconovo acquired XXX companies to date.
Last acquisition by Iconovo was XXXXXXXX, XXXXX XXXXX XXXXXX . Iconovo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Iconovo founded? | Iconovo was founded in 2013. |
| Where is Iconovo headquartered? | Iconovo is headquartered in Sweden. |
| How many employees does Iconovo have? | As of today, Iconovo has 25 employees. |
| Is Iconovo publicy listed? | Yes, Iconovo is a public company listed on STO. |
| What is the stock symbol of Iconovo? | Iconovo trades under ICO ticker. |
| When did Iconovo go public? | Iconovo went public in 2018. |
| Who are competitors of Iconovo? | Similar companies to Iconovo include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Iconovo? | Iconovo's current market cap is $2.9M |
| What is the current revenue of Iconovo? | Iconovo's last 12 months revenue is $1.9M. |
| What is the current revenue growth of Iconovo? | Iconovo revenue growth (NTM/LTM) is 212%. |
| What is the current EV/Revenue multiple of Iconovo? | Current revenue multiple of Iconovo is 0.6x. |
| Is Iconovo profitable? | Yes, Iconovo is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Iconovo? | Iconovo's last 12 months EBITDA is -$1.7M. |
| What is Iconovo's EBITDA margin? | Iconovo's last 12 months EBITDA margin is -92%. |
| What is the current EV/EBITDA multiple of Iconovo? | Current EBITDA multiple of Iconovo is -0.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
